These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 18001259)

  • 1. The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes.
    Mikhailidis DP; Press M
    Expert Opin Pharmacother; 2007 Dec; 8(17):3009-20. PubMed ID: 18001259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The importance of treating cardiometabolic risk factors in patients with type 2 diabetes.
    Barnett AH
    Diab Vasc Dis Res; 2008 Mar; 5(1):9-14. PubMed ID: 18398806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
    Basile J; Houston M; Ferrario CM
    J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes.
    Després JP
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S53-61. PubMed ID: 14502101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overweight and obesity: the pathogenesis of cardiometabolic risk.
    Bray GA; Clearfield MB; Fintel DJ; Nelinson DS
    Clin Cornerstone; 2009; 9(4):30-40; discussion 41-2. PubMed ID: 19789062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycystic ovary syndrome, adipose tissue and metabolic syndrome.
    Delitala AP; Capobianco G; Delitala G; Cherchi PL; Dessole S
    Arch Gynecol Obstet; 2017 Sep; 296(3):405-419. PubMed ID: 28643028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intra-abdominal adiposity, inflammation, and cardiovascular risk: new insight into global cardiometabolic risk.
    Calabro P; Yeh ET
    Curr Hypertens Rep; 2008 Feb; 10(1):32-8. PubMed ID: 18367024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The adiponectin to leptin ratio, a still unrecognized biomarker of insulin resistance and cardiometabolic risk].
    Vatier C; Antuna-Puente B; Fellahi S; Vigouroux C; Capeau J; Bastard JP;
    Ann Biol Clin (Paris); 2020 Jun; 78(3):265-268. PubMed ID: 32420886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
    Greenberg AS
    J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Fat mass expansion, fatty acids and adipokines: metabolic markers and risk factors for cardiovascular pathologies].
    Lafontan M
    Ann Pharm Fr; 2013 Jan; 71(1):13-26. PubMed ID: 23348852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
    Ndumele CE; Pradhan AD; Ridker PM
    J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organokines in disease.
    Chung HS; Choi KM
    Adv Clin Chem; 2020; 94():261-321. PubMed ID: 31952573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular risk of adipokines: a review.
    Dutheil F; Gordon BA; Naughton G; Crendal E; Courteix D; Chaplais E; Thivel D; Lac G; Benson AC
    J Int Med Res; 2018 Jun; 46(6):2082-2095. PubMed ID: 28974138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipokines at the crossroad between obesity and cardiovascular disease.
    Molica F; Morel S; Kwak BR; Rohner-Jeanrenaud F; Steffens S
    Thromb Haemost; 2015 Mar; 113(3):553-66. PubMed ID: 25338625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipose-Vascular Coupling and Potential Therapeutics.
    Gollasch M
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():417-436. PubMed ID: 27732801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clusterin and Its Role in Insulin Resistance and the Cardiometabolic Syndrome.
    Wittwer J; Bradley D
    Front Immunol; 2021; 12():612496. PubMed ID: 33717095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
    Esser N; Paquot N; Scheen AJ
    Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominal adiposity and cardiometabolic risk: do we have all the answers?
    Haffner SM
    Am J Med; 2007 Sep; 120(9 Suppl 1):S10-6; discussion S16-7. PubMed ID: 17720354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adipokines--targeting a root cause of cardiometabolic risk.
    Bakhai A
    QJM; 2008 Oct; 101(10):767-76. PubMed ID: 18550581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of aspirin therapy in patients with the cardiometabolic syndrome and diabetes.
    Gardner M; Palmer J; Manrique C; Lastra G; Gardner DW; Sowers JR
    J Cardiometab Syndr; 2009; 4(2):96-101. PubMed ID: 19614796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.